2025 Q3 -tulosraportti
99 päivää sitten
‧1 t 0 min
Tarjoustasot
Määrä
Osto
2 836
Myynti
Määrä
484
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
19,38VWAP
Alin
17,5VaihtoMäärä
389,7 36 254 392
VWAP
Ylin
19,38Alin
17,5VaihtoMäärä
389,7 36 254 392
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 23.2. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 3.11.2025 | ||
2025 Q2 -tulosraportti 4.8.2025 | ||
Vuosittainen yhtiökokous 2025 12.6.2025 | ||
2025 Q1 -tulosraportti 5.5.2025 | ||
2024 Q4 -tulosraportti 24.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·51 min sittenI really hope they get such a beating in the upcoming lawsuit with Novo that they realize they shouldn't freeload on others, really good if they are sentenced to pay back so much that they go bankrupt, yes, you guessed right, I myself have shares in Novo Nordisk
·2 t sittenWhat do you think about the future here? I'm 65% in the red and don't know what to do.·1 t sittenFocus on what the company does, all that happens in the news is just «mr.market» having some mood swings. Marcet cap slightly over 3 billion, earned 1.5 billion last year, still growing a lot in customer numbers and revenue despite the glp-styret. Recently launched labs seem promising, cancer-tests that are making progress. I have bought a bit more, but not much. Just took advantage of the sale. Don't let emotions make the buys and sells 🤝
·15 min sittenI think you should read their financial statements - they have not earned 1.5 billion, neither last year nor all years combined since the company was founded. They had a revenue of approx. 1.5 billion last year. Their earnings measured against revenue are extremely low.
·2 t sitten · MuokattuI own shares in HIMS, and it's no secret here that I am extremely bullish on the company. Therefore, in light of Novo's lawsuit, I have made a video about why I have bought more HIMS. https://www.youtube.com/watch?v=FUikNVIdoW8·2 t sittenBut the management is good, because they copy a patented product and sell it for 1/3 of the price?.... In my world, it fits reasonably well that Hims must be considered lazy or incompetent, as they either don't care about the law or have no knowledge of what a patent is? If you look at key figures for Hims, it certainly doesn't show that the company is being traded as if they are about to go bankrupt. They are traded based on the uncertainty of what economic consequences it might have for Hims when they are sued. Being sued is, of course, not something an investor or company is interested in. Regarding whether the management is incompetent, it must be said that there is a fair assessment here that they are. Why else make a big announcement that you are offering the Wegovy pill for 49 dollars per month, and 2 days later remove the product. So, laziness and/or lack of knowledge must be said to be present in the management, no matter how you look at it. Personally, I have written previously that I would not be surprised if the company does not exist within the next 5 years, precisely because of the management's actions and the way their business is run - if they want to survive, they must sell patent-protected medicine via agreements with e.g. Novo, Lilly and others. Or they must sell medicine that has gone off patent. This is, of course, just my own opinion and view :)
11 t sitten11 t sittenThinking to buy at 10 to 15 range any suggestions? Thanks in advance
·6 t sitten · Muokattu"Lose money for the firm, and I will be understanding. Lose a shred of reputation for the firm, and I will be ruthless". - Buffet The company's reputation has taken a hit, but it will not go bankrupt and it continues to make money. If you have a long-term perspective, it could be a good opportunity.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
99 päivää sitten
‧1 t 0 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·51 min sittenI really hope they get such a beating in the upcoming lawsuit with Novo that they realize they shouldn't freeload on others, really good if they are sentenced to pay back so much that they go bankrupt, yes, you guessed right, I myself have shares in Novo Nordisk
- ·2 t sittenWhat do you think about the future here? I'm 65% in the red and don't know what to do.·1 t sittenFocus on what the company does, all that happens in the news is just «mr.market» having some mood swings. Marcet cap slightly over 3 billion, earned 1.5 billion last year, still growing a lot in customer numbers and revenue despite the glp-styret. Recently launched labs seem promising, cancer-tests that are making progress. I have bought a bit more, but not much. Just took advantage of the sale. Don't let emotions make the buys and sells 🤝·15 min sittenI think you should read their financial statements - they have not earned 1.5 billion, neither last year nor all years combined since the company was founded. They had a revenue of approx. 1.5 billion last year. Their earnings measured against revenue are extremely low.
- ·2 t sitten · MuokattuI own shares in HIMS, and it's no secret here that I am extremely bullish on the company. Therefore, in light of Novo's lawsuit, I have made a video about why I have bought more HIMS. https://www.youtube.com/watch?v=FUikNVIdoW8·2 t sittenBut the management is good, because they copy a patented product and sell it for 1/3 of the price?.... In my world, it fits reasonably well that Hims must be considered lazy or incompetent, as they either don't care about the law or have no knowledge of what a patent is? If you look at key figures for Hims, it certainly doesn't show that the company is being traded as if they are about to go bankrupt. They are traded based on the uncertainty of what economic consequences it might have for Hims when they are sued. Being sued is, of course, not something an investor or company is interested in. Regarding whether the management is incompetent, it must be said that there is a fair assessment here that they are. Why else make a big announcement that you are offering the Wegovy pill for 49 dollars per month, and 2 days later remove the product. So, laziness and/or lack of knowledge must be said to be present in the management, no matter how you look at it. Personally, I have written previously that I would not be surprised if the company does not exist within the next 5 years, precisely because of the management's actions and the way their business is run - if they want to survive, they must sell patent-protected medicine via agreements with e.g. Novo, Lilly and others. Or they must sell medicine that has gone off patent. This is, of course, just my own opinion and view :)
- 11 t sitten11 t sittenThinking to buy at 10 to 15 range any suggestions? Thanks in advance·6 t sitten · Muokattu"Lose money for the firm, and I will be understanding. Lose a shred of reputation for the firm, and I will be ruthless". - Buffet The company's reputation has taken a hit, but it will not go bankrupt and it continues to make money. If you have a long-term perspective, it could be a good opportunity.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
2 836
Myynti
Määrä
484
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
19,38VWAP
Alin
17,5VaihtoMäärä
389,7 36 254 392
VWAP
Ylin
19,38Alin
17,5VaihtoMäärä
389,7 36 254 392
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 23.2. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 3.11.2025 | ||
2025 Q2 -tulosraportti 4.8.2025 | ||
Vuosittainen yhtiökokous 2025 12.6.2025 | ||
2025 Q1 -tulosraportti 5.5.2025 | ||
2024 Q4 -tulosraportti 24.2.2025 |
2025 Q3 -tulosraportti
99 päivää sitten
‧1 t 0 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 23.2. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 3.11.2025 | ||
2025 Q2 -tulosraportti 4.8.2025 | ||
Vuosittainen yhtiökokous 2025 12.6.2025 | ||
2025 Q1 -tulosraportti 5.5.2025 | ||
2024 Q4 -tulosraportti 24.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·51 min sittenI really hope they get such a beating in the upcoming lawsuit with Novo that they realize they shouldn't freeload on others, really good if they are sentenced to pay back so much that they go bankrupt, yes, you guessed right, I myself have shares in Novo Nordisk
- ·2 t sittenWhat do you think about the future here? I'm 65% in the red and don't know what to do.·1 t sittenFocus on what the company does, all that happens in the news is just «mr.market» having some mood swings. Marcet cap slightly over 3 billion, earned 1.5 billion last year, still growing a lot in customer numbers and revenue despite the glp-styret. Recently launched labs seem promising, cancer-tests that are making progress. I have bought a bit more, but not much. Just took advantage of the sale. Don't let emotions make the buys and sells 🤝·15 min sittenI think you should read their financial statements - they have not earned 1.5 billion, neither last year nor all years combined since the company was founded. They had a revenue of approx. 1.5 billion last year. Their earnings measured against revenue are extremely low.
- ·2 t sitten · MuokattuI own shares in HIMS, and it's no secret here that I am extremely bullish on the company. Therefore, in light of Novo's lawsuit, I have made a video about why I have bought more HIMS. https://www.youtube.com/watch?v=FUikNVIdoW8·2 t sittenBut the management is good, because they copy a patented product and sell it for 1/3 of the price?.... In my world, it fits reasonably well that Hims must be considered lazy or incompetent, as they either don't care about the law or have no knowledge of what a patent is? If you look at key figures for Hims, it certainly doesn't show that the company is being traded as if they are about to go bankrupt. They are traded based on the uncertainty of what economic consequences it might have for Hims when they are sued. Being sued is, of course, not something an investor or company is interested in. Regarding whether the management is incompetent, it must be said that there is a fair assessment here that they are. Why else make a big announcement that you are offering the Wegovy pill for 49 dollars per month, and 2 days later remove the product. So, laziness and/or lack of knowledge must be said to be present in the management, no matter how you look at it. Personally, I have written previously that I would not be surprised if the company does not exist within the next 5 years, precisely because of the management's actions and the way their business is run - if they want to survive, they must sell patent-protected medicine via agreements with e.g. Novo, Lilly and others. Or they must sell medicine that has gone off patent. This is, of course, just my own opinion and view :)
- 11 t sitten11 t sittenThinking to buy at 10 to 15 range any suggestions? Thanks in advance·6 t sitten · Muokattu"Lose money for the firm, and I will be understanding. Lose a shred of reputation for the firm, and I will be ruthless". - Buffet The company's reputation has taken a hit, but it will not go bankrupt and it continues to make money. If you have a long-term perspective, it could be a good opportunity.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
2 836
Myynti
Määrä
484
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
19,38VWAP
Alin
17,5VaihtoMäärä
389,7 36 254 392
VWAP
Ylin
19,38Alin
17,5VaihtoMäärä
389,7 36 254 392
Välittäjätilasto
Dataa ei löytynyt